寺下 友佳代 (テラシタ ユカヨ)

北海道大学病院 小児・周産・女性科助教

研究者基本情報

■ 学位
  • 医学博士, 北海道大学, 2020年03月
■ URL
researchmap URLホームページURL■ ID 各種
ORCID IDJ-Global ID■ 研究キーワード・分野
研究分野
  • ライフサイエンス, 血液、腫瘍内科学
  • ライフサイエンス, 胎児医学、小児成育学
■ 担当教育組織

研究活動情報

■ 論文
  • Trametinib Plus Azacitidine as Bridging Therapy to Hematopoietic Stem Cell Transplantation in an Infant With PTPN11‐Mutated Juvenile Myelomonocytic Leukemia
    Hisato Segoe; Jutaro Abe; Shinsuke Hirabayashi; Risa Nakashima; Kazumi Oura; Yukayo Terashita; Yuko Cho; Daichi Sajiki; Hideki Muramatsu; Atsushi Manabe
    Pediatric Blood & Cancer, 2026年10月14日
    研究論文(学術雑誌)
  • Combined Treatment of Intracerebroventricular Enzyme Replacement and Cord Blood Transplantation in Patients with Mucopolysaccharidosis Type II Diagnosed by Newborn Screening
    Yuki Ueda; Shunsuke Hirabayashi; Satoshi Yamada; Sachiko Nakakubo; Midori Nakajima; Takeru Goto; Jutaro Abe; Yukayo Terashita; Atsushi Manabe; Torayuki Okuyama; Kiyoshi Egawa
    2026年05月19日, [査読有り]
  • Therapeutic Courses of Presumed Intracranial Immature Teratoma Diagnosed Based on Increased Alpha-Fetoprotein.
    Shigeru Yamaguchi; Yukitomo Ishi; Michinari Okamoto; Sogo Oki; Ryosuke Sawaya; Hiroaki Motegi; Yukayo Terashita; Shinsuke Hirabayashi; Kentaro Nishioka; Takayuki Hashimoto; Hiromi Okada; Emi Takakuwa; Hidefumi Aoyama; Atsushi Manabe; Miki Fujimura
    Journal of child neurology, 8830738261446144, 8830738261446144, 2026年05月07日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Intracranial immature teratoma (ImT) is one of the non-germinomatous germ cell tumors, and elevated serum alpha-fetoprotein (AFP) value is a crucial clinical diagnostic indicator of ImT. In this retrospective study conducted among patients diagnosed with intracranial ImT, diagnostic procedures, therapeutic courses, histopathologic diagnosis, and prognosis were reviewed. Among 106 patients with intracranial germ cell tumors, 11 were diagnosed with ImT and treated since 2000. ImT was diagnosed via biopsy or based on mild or moderate serum AFP elevation of 10-500 ng/mL. Complete remission via chemoradiotherapy was achieved in only 2 patients (18%); 5 patients (45%) suffered from growing disease during treatment; and 7 patients required salvage tumor resection. The 10-year progression-free and overall survival rates were 76.2% and 87.5%, respectively. The therapeutic courses of ImT varied. Notably, cases in which treatment was applied considering ImT were highly prone to experience growing disease during treatment.
  • Endocrine disorders in pediatric medulloblastoma survivors treated with X-ray or proton beam therapy: a single-institution retrospective study.
    Naoya Kaneko; Shuntaro Morikawa; Megumi Endo; Nozomi Hishimura; Liu Zhitong; Takeshi Yamaguchi; Hisato Segoe; Jutaro Abe; Kazumi Oura; Saori Sawai; Minako Sugiyama; Yukayo Terashita; Shinsuke Hirabayashi; Yuko Cho; Akie Nakamura; Yukitomo Ishi; Seishin Takao; Yuto Matsuo; Shigeru Yamaguchi; Takayuki Hashimoto; Atsushi Manabe
    Endocrine journal, 2026年04月10日, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌), Medulloblastoma, a common pediatric central nervous system disease, is managed with surgery, chemotherapy, and craniospinal irradiation (CSI) delivered with either X-rays or protons. Proton-beam CSI, introduced to protect the surrounding tissues, may reduce endocrine toxicity. In this single-institution retrospective observational study, we evaluated adverse endocrine events in 14 patients diagnosed with medulloblastoma before 13 years of age: 9 and 5 received X-ray and proton beam CSI, respectively. In the X-ray therapy group, the median age at diagnosis was 4.2 (range: 1.4-12.5) years, the median post-radiation follow-up was 19.5 (9.7-34.7) years, and the median CSI dose was 25.2 (23.4-36.0) Gy. The proton beam therapy group showed corresponding medians of 9.4 (5.3-11.7) years, 6.9 (5.4-8.1) years, and 23.4 (23.4-36.0) Gy. Five years after radiation therapy completion, the incidence of growth hormone deficiency was 44% (4/9) and 60% (3/5) in the X-ray and proton beam therapy groups, respectively. However, primary hypothyroidism and central hypothyroidism were exclusively observed in the X-ray therapy group, in 33% (3/9) and 11% (1/9) of patients. Given the short follow-up period for the proton beam therapy group, the difference in the occurrence rates of gonadal dysfunction and adrenal insufficiency is currently unknown. Our findings suggest that, at ≤5 years after the completion of radiation therapy, radiation-induced hypothyroidism was observed only in patients treated with X-ray therapy and not in those treated with proton beam therapy. Further studies with larger cohorts and longer follow-up periods are required to clarify this possible advantage and to refine radiation therapy protocols.
  • Proton Whole Lung Irradiation for a Patient With Metastatic Ewing Sarcoma.
    Yusuke Imanaka; Sho Kurihara; Yukayo Terashita; Masataka Hasegawa; Hiroshi Taguchi; Seishin Takao; Shuhei Karakawa; Takayuki Hashimoto; Atsushi Manabe; Satoshi Okada; Yoko Mizoguchi
    Pediatric blood & cancer, e70160, 2026年02月22日, [査読有り], [国際誌]
    英語
  • Genomic Profiling of Pediatric Solid Tumors With a Dual DNA/RNA Panel: JCCG-TOP2 Study.
    Kayoko Tao; Takako Yoshioka; Miho Kato; Kazuyuki Komatsu; Shinichi Tsujimoto; Kenichi Sakamoto; Kazuki Tanimura; Minako Sugiyama; Masahiro Sekiguchi; Yoshiko Nakano; Yoshihiro Otani; Yasushi Yatabe; Akihiko Yoshida; Hajime Okita; Junko Hirato; Kenichi Kohashi; Yukichi Tanaka; Shinji Kohsaka; Takashi Kubo; Kuniko Sunami; Makoto Hirata; Shuichi Tsutsumi; Hiroyuki Aburatani; Katsuyoshi Koh; Masahiro Hirayama; Shuhei Karakawa; Yukayo Terashita; Hiroyuki Fujisaki; Takeshi Yagi; Akihiro Yoneda; Shinji Mochizuki; Hiroyuki Shichino; Tatsuya Suzuki; Tetsuya Takimoto; Koichi Ichimura; Chitose Ogawa; Kimikazu Matsumoto; Hitoshi Ichikawa; Motohiro Kato
    Cancer science, 117, 2, 522, 535, 2026年02月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), To develop an optimized genomic medicine platform for pediatric cancers, a nationwide cancer genome profiling project was conducted from January 2022 to February 2023 in collaboration with the Japan Children's Cancer Group. This prospective observational study analyzed matched blood and FFPE tumor samples from patients aged 0-29 years with solid tumors. Genomic analysis used the TOP2 hybrid capture-enrichment system, targeting 737 and 455 genes in the DNA and RNA panels, along with allele-specific genome copy number alterations. A total of 210 patients from 50 institutions were enrolled across Japan (median age, 8 years; range, 0-25). Of these, 154 (77%) were enrolled at diagnosis or during/after initial treatment and 56 (27%) at disease progression or relapse. The TOP2 findings had great benefits in clarifying the diagnosis of pediatric solid tumors. Among the 204 patients with genomic results, 147 (72%) had potentially actionable findings, including diagnostic, prognostic, and therapeutic findings in 111 (54%), 61 (30%), and 64 (31%), respectively. Oncogenic fusions were noted in 45 (23%) patients. A copy number alteration was identified in at least one genomic region in 170 (83%) patients. Two patients exhibited a high tumor mutation burden. Seventeen (8%) patients harbored a germline pathogenic/likely pathogenic variant in cancer-predisposing genes. This study highlighted the feasibility of implementing a nationwide precision medicine platform and the clinical utility of the TOP2 system for pediatric cancers. The results support the integration of genomic data into the standard clinical care of pediatric patients with cancer, both at diagnosis and at relapse.
  • Endocrine dysfunction induced by anti-PD-1 antibody and tyrosine kinase inhibitor in a pediatric patient with renal cell carcinoma
    Megumi Endo; Shuntaro Morikawa; Naoya Kaneko; Nozomi Hishimura; Liu Zhitong; Takeshi Yamaguchi; Atsushi Yamaguchi; Hisato Segoe; Jutaro Abe; Kazumi Oura; Yukayo Terashita; Yuko Cho; Shinsuke Hirabayashi; Atsushi Manabe
    Clinical Pediatric Endocrinology, Japanese Society for Pediatric Endocrinology, 2026年, [査読有り]
    研究論文(学術雑誌)
  • Comprehensive Cancer Genomic Profiling and Germline Predisposition Analysis in Pediatric Cancer: Insights From the Hokkaido Pediatric Cancer Consortium, Japan
    Yusuke Saito; Yukayo Terashita; Toraji Amano; Minako Sugiyama; Kazumi Oura; Masataka Hasegawa; Jutaro Abe; Shinsuke Hirabayashi; Yuko Cho; Shin Ariga; Kanako Hagio; Yoshihito Ohhara; Junko Kikuchi; Yukitomo Ishi; Shigeru Yamaguchi; Hiromi Kanno-Okada; Emi Takakuwa; Zen-Ichi Tanei; Yuka Shibata; Mio Mukainakano; Honami Fujita; Kanako C. Hatanaka; Yutaka Hatanaka; Akira Takebayashi; Yusuke Akane; Masaki Yamamoto; Takeo Sarashina; Shinya Tanaka; Takahiro Yamada; Ichiro Kinoshita; Atsushi Manabe
    PEDIATRIC BLOOD & CANCER, 72, S850, S850, 2025年12月
    英語
  • The Safety and Efficacy of Ruxolitinib in an Infant With Familial Hemophagocytic Syndrome Type 3: A Bridging Therapy Toward Hematopoietic Cell Transplantation and Treatment of Post‐Transplant Complications, Including Sinusoidal Obstruction Syndrome
    Kazuki Takahashi; Shinsuke Hirabayashi; Masahiro Ueki; Masataka Hasegawa; Hiroki Ohata; Shunichiro Takezaki; Yukayo Terashita; Yuko Cho; Atsushi Manabe
    Pediatric Blood & Cancer, 2025年12月, [査読有り]
    研究論文(学術雑誌)
  • Pediatric Pulmonary Hypertension Associated With Treatment of Myeloproliferative Disorders and Malignant Tumors.
    Ayako Chida-Nagai; Yukayo Terashita; Shinsuke Hirabayashi; Hirokuni Yamazawa; Yuko Cho; Atsushi Manabe
    Pulmonary circulation, 15, 3, e70165, 2025年07月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Pulmonary hypertension (PH) is a severe complication observed in pediatric patients after hematopoietic cell transplantation or chemotherapy. A review of records at Hokkaido University Hospital (2014-2024) identified four cases of PH, each with different etiologies, including pulmonary arterial hypertension, pulmonary veno-occlusive disease, and microthromboembolism. Contributing factors included splenic atrophy, corticosteroid-responsive inflammation, and potential drug-induced vascular remodeling. Although transient PH usually resolves, late-onset PH emphasizes the need for long-term echocardiographic monitoring. These findings underscore the importance of individualized management, avoiding pulmonary vasodilators without proper evaluation, and addressing underlying conditions such as thrombotic microangiopathy or interstitial lung disease.
  • Near-infrared photoimmunotherapy using antiGD2 antibody for neuroblastoma and osteosarcoma
    Jimei Zhao; Kohei Nakajima; Masahiro Ueki; Yukayo Terashita; Shinsuke Hirabayashi; Yuko Cho; Mikako Ogawa; Atsushi Manabe
    EJC Paediatric Oncology, 5, 100233, 100233, Elsevier BV, 2025年06月, [査読有り]
    研究論文(学術雑誌)
  • Ultrasonographic scoring system for SOS/VOD in pediatric hematopoietic stem cell transplant recipients.
    Mutsumi Nishida; Shinsuke Hirabayashi; Takahito Iwai; Megumi Sato; Yusuke Kudo; Satomi Omotehara; Tatsunori Horie; Ryosuke Sakano; Yukayo Terashita; Yuko Cho; Atsushi Manabe; Takanori Teshima
    International journal of hematology, 2025年04月26日, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌), Sinusoidal obstruction syndrome (SOS)/veno-occlusive disease (VOD) is a serious complication following hematopoietic stem cell transplantation. It is more common in children, with an incidence of approximately 20% compared to 10% in adult patients. While the Hokkaido ultrasonography (US)-based scoring system (HokUS-10 and HokUS-6) has proven effective in diagnosing SOS/VOD in adults, its utility in children remains uncertain. This study evaluated the utility of the HokUS-10/6 scoring systems in diagnosing pediatric SOS/VOD (pSOS/VOD) in a cohort of 99 patients, including 13 diagnosed with pSOS/VOD. Hyperbilirubinemia (> 2 mg/dL) was observed in only three patients (23%), whereas transfusion-refractory thrombocytopenia, hepatomegaly, and ascites were observed in all 13 patients. When the cutoff values for HokUS-10 and HokUS-6 scores were set at 4 and 2, the respective areas under the curve were 0.977 and 0.957. The sensitivity and specificity were 100% and 80% for HokUS-10, and 77% and 97% for HokUS-6, respectively. The simplified HokUS-6 may be a practical tool for diagnosing pSOS/VOD when use of the HokUS-10 scoring system is not feasible. HokUS-10/6 is important for early detection of pSOS/VOD during regular examinations and plays a valuable role in the diagnosis of clinical pSOS/VOD.
  • Mature teratoma with a germinoma component presenting with undetectable placental alkaline phosphatase in cerebrospinal fluid: illustrative case
    Sogo Oki; Shigeru Yamaguchi; Michinari Okamoto; Yukitomo Ishi; Hiromi Kanno-Okada; Emi Takakuwa; Yukayo Terashita; Shinsuke Hirabayashi; Kentaro Nishioka; Takayuki Hashimoto; Atsushi Manabe; Miki Fujimura
    Journal of Neurosurgery: Case Lessons, 2025年02月24日, [査読有り]
    研究論文(学術雑誌)
  • Long-term outcome and social-intellectual ability of patients with basal ganglia germinoma
    Michinari Okamoto; Shigeru Yamaguchi; Ryosuke Sawaya; Yukitomo Ishi; Hiroaki Motegi; Yukayo Terashita; Minako Sugiyama; Yuko Cho; Kentaro Nishioka; Takashi Mori; Takayuki Hashimoto; Hidefumi Aoyama; Atsushi Manabe; Miki Fujimura
    Pediatric Neurology, Elsevier BV, 2025年01月
    研究論文(学術雑誌)
  • Comparison of busulfan pharmacokinetics between four-times-daily and once-daily administration in pediatric patients: a preliminary prospective observational trial
    Atsushi Yamaguchi; Shinsuke Hirabayashi; Kazuko Niki; Keisuke Kagami; Yukayo Terashita; Yuko Cho; Atsushi Manabe; Mitsuru Sugawara; Yoh Takekuma
    International Journal of Hematology, Springer Science and Business Media LLC, 2024年12月03日, [査読有り]
    研究論文(学術雑誌)
  • Increased response to granulocyte-macrophage colony-stimulating factor in peripheral blood cells and transient manifestations mimicking juvenile myelomonocytic leukemia in a male patient with NEMO deficiency caused by a deep intronic pathogenic variant of IKBKG.
    Masahiro Ueki; Shinsuke Hirabayashi; Yoshitaka Honda; Shunichiro Takezaki; Hiroki Ohata; Shimaa Said Mohamed Ali Abdrabou; Saori Sawai; Yukayo Terashita; Yuko Cho; Hideki Muramatsu; Kazushi Izawa; Takahiro Yasumi; Yoshiyuki Takahashi; Masafumi Yamada; Atsushi Manabe
    Immunological medicine, 1, 8, 2024年11月01日, [国際誌]
    英語, 研究論文(学術雑誌), X-linked NF-κB essential modulator (NEMO) deficiency is a primary immunodeficiency characterized by combined immunodeficiency and ectodermal dysplasia. Monocytes from the patients demonstrate a severely impaired response to tissue necrosis factor or lipopolysaccharide, whereas hyper-inflammation is found in some patients. Juvenile myelomonocytic leukemia (JMML) is a pediatric malignancy caused by hypersensitivity to granulocyte-macrophage colony-stimulating factor (GM-CSF) and aberrant RAS signaling activation. Patients with JMML demonstrate characteristic manifestations such as splenomegaly, monocytosis and the presence of myeloid or erythroid precursors in the peripheral blood. Here, we present the case of a male infant with ectodermal dysplasia, bacterial septicemia, Pneumocystis pneumonia, severe inflammation and transient manifestations mimicking JMML. Genetic analysis revealed a deep intronic germline variant of IKBKG. Full-length IKBKG cDNA and NEMO protein expression were almost inexistent. Peripheral mononuclear cells (PBMCs) from the patient showed increased RAS signaling activation with GM-CSF or Phorbol 12-myristate 13-acetate without the RAS-associated gene variant, although the increased RAS signaling activation in induced-pluripotent stem cell-derived myeloid lineage and bone marrow-derived mesenchymal cells was not evident. The patient with NEMO deficiency demonstrated JMML-like manifestation and severe inflammation. PBMCs of the patient demonstrated increased RAS signaling activation with unknown pathophysiology.
  • Serum 5-S-cysteinyldopa as a predictive biomarker for stem cell transplantation-related complications in children and young adults
    Yukayo Terashita; Akihiro Iguchi; Minako Sugiyama; Yuko Cho; Houman Goudarzi; Isao Yokota; Atsushi Manabe
    Blood Cell Therapy, 2024年09月, [査読有り], [筆頭著者]
    英語
  • Survey of Transitional Care Between Pediatrics and Obstetrics/Gynecology in Japan.
    Kentaro Nakamura; Yukayo Terashita; Atsushi Manabe; Nao Suzuki
    Journal of adolescent and young adult oncology, 13, 3, 523, 533, 2024年06月, [国際誌]
    英語, 研究論文(学術雑誌), Purpose: This study's aim was to determine the actual status of transitional care for patients with pediatric cancer (PPCs) in Japan by surveying obstetricians/gynecologists. Methods: A questionnaire survey on transitional medicine was conducted in the form of an online questionnaire at 579 major training facilities nationwide, which were registered with the Japanese Society of Obstetrics and Gynecology. Results: While 40% of the facilities had received referrals for PPCs, only 13% provided transitional care specifically for PPCs. The most common problems with referrals were related to "insufficient explanation." In addition, at facilities with no experience treating PPCs, many respondents commented that they did not know how to follow the progression of the disease. Regarding the necessity of obstetrics/gynecology visits for PPCs, more than half of the respondents at facilities with experience treating PPCs answered that such visits were "necessary"; only 1% answered that they were "unnecessary." On the other hand, 37% of the facilities that had no experience treating PPCs answered that it was "necessary," whereas 4% answered that it was "unnecessary." Conclusions: This survey of the actual status of transitional care between pediatrics and obstetrics/gynecology in Japan identified issues to be addressed for the spread of transitional care. The results suggest that, in the future, health care professionals need education to increase their knowledge, and that patient education that leads to patients' awareness of their own self-management is necessary.
  • 視路視床下部神経膠腫再発に対する化学療法を中心とした治療戦略
    山口 秀; 伊師 雪友; 茂木 洋晃; 大木 聡悟; 寺下 友佳代; 長谷河 昌孝; 長 祐子; 平林 真介; 真部 淳; 藤村 幹
    小児の脳神経, 49, 3, 81, 87, 一般社団法人 日本小児神経外科学会, 2024年
    日本語, 視路視床下部低悪性度神経膠腫(OPHG)に対して,再発時の治療に関して化学療法を中心とした治療戦略としている.本治療戦略で治療を行ったOPHG症例の再発時化学療法の治療効果を中心に検討した.2007年以降の初発18例のうち12例で再発を認めた(中央値29か月).再発時の治療として化学療法が8例で選択され,カルボプラチンを中心とした化学療法レジメンが最も有用であり,6例中4例で治療効果が得られた.本治療戦略において視機能を含めた神経機能予後は良好であったが,腎毒性を中心とした合併症が課題である.
  • 当院におけるキャンサーボードを中心とした小児脳腫瘍診療体制の構築
    山口 秀; 伊師 雪友; 茂木 洋晃; 寺下 友佳代; 平林 真介; 橋本 孝之; 真部 淳; 藤村 幹
    日本小児血液・がん学会雑誌, 61, 2, 154, 158, 日本小児血液・がん学会, 2024年
    日本語, 小児脳腫瘍は希少疾患である.医師個人が経験できる症例は限られているため,個人の経験と直感に基づいた治療方針の決定は患者に有益とはならず,可能な限りの治療の均てん化は必須であろう.そのためには集約化のみでなく,一例毎の情報と経験の共有が大変重要となる.

    当院では小児脳腫瘍の診断治療にあたり,脳神経外科・小児科・放射線治療科を主体とする小児脳腫瘍キャンサーボードを中心としたシームレスな診療体制を構築している.週1回定期的に開催し,治療中の患者の情報共有,新患紹介と治療方針の検討,転科調整等を行うことで,経験症例の共有・治療効果の客観性の確保・治療タイムラグの減少が可能となっている.全症例を本ボードで検討し,診療科に拘らない適切かつ迅速な初期対応・治療を志している.

    2013年に当院が小児がん拠点病院に選定されてから,161例の20歳未満初発小児脳腫瘍患者の治療を行った.初発から対応したのは150例であり,内訳は低悪性度神経膠腫28例,悪性神経膠腫22例,上衣腫9例,胚細胞腫瘍27例,髄芽腫等の胎児性腫瘍21例等であった.初発時診断では,本ボード上での協議で9例(胚細胞腫瘍6例,低悪性度神経膠腫3例)が組織診断なしでの診断確定を合意し,後療法を施行した.治療後残存病変に対して追加摘出術に関しても,必要性や時期は本ボード上の協議にて決定された.年齢に応じた治療方針や晩期障害を見据えた化学療法・放射線治療の選択,他施設からの相談症例に関しても本ボードでの討議事項である.治療に関わる複数科医師での合意・共通疾患認識が重要であり,本ボードがその中心の役割を果たしている.
  • Sunburst appearanceを呈する頭蓋骨腫瘤を契機に発見された神経芽腫の1例
    北川 悠; 竹中 淳規; 渡邊 史郎; 平田 健司; 内山 裕子; 木村 理奈; 中川 純一; 池辺 洋平; 長谷河 昌孝; 澤井 彩織; 寺下 友佳代; 杉山 未奈子; 平林 真介; 長 祐子; 山口 秀; 真部 淳; 工藤 與亮
    北海道放射線医学雑誌, 3, 33, 36, (NPO)メディカルイメージラボ, 2023年03月
    日本語
  • The heterozygous NUDT15 variant is not associated with the severity of 6-mercaptopurine-related side effects in early intensification therapy for childhood acute lymphoblastic leukemia
    Jimei Zhao; Masahiro Ueki; Saori Sawai; Minako Sugiyama; Yukayo Terashita; Shinsuke Hirabayashi; Yuko Cho; Ryoji Kobayashi; Yoichi Tanaka; Atsushi Manabe
    EJC Paediatric Oncology, 1, 100006, 100006, Elsevier BV, 2023年
    研究論文(学術雑誌)
  • Central nervous system complications and white matter lesions by brain MRI in pediatric hematological malignancies
    Minako Sugiyama; Shinsuke Hirabayashi; Yukayo Terashita; Yuko Cho; Akihiro Iguchi; Atsushi Manabe
    2022年03月30日
  • Hepatoblastoma with bone/bone marrow metastasis in Li-Fraumeni syndrome patient.
    Masataka Hasegawa; Minako Sugiyama; Yukayo Terashita; Yuko Cho; Atsushi Manabe
    Pediatrics international : official journal of the Japan Pediatric Society, 64, 1, e15135, 2022年01月, [国際誌]
    英語, 研究論文(学術雑誌)
  • Notable therapeutic response in a patient with systemic juvenile xanthogranuloma with KIF5B-ALK fusion.
    Minako Sugiyama; Shinsuke Hirabayashi; Yukitomo Ishi; Junko Kikuchi; Ayako Ishikura; Hiroaki Motegi; Yuki Ueda; Saori Sawai; Kazuya Hara; Yukayo Terashita; Yuko Cho; Emi Takakuwa; Shohei Honda; Shigeru Yamaguchi; Ichiro Kinoshita; Atsushi Manabe
    Pediatric blood & cancer, 68, 11, e29227, 2021年11月, [国際誌]
    英語
  • Diagnostic Capability of Cerebrospinal Fluid-Placental Alkaline Phosphatase Value in Intracranial Germ Cell Tumor.
    Michinari Okamoto; Shigeru Yamaguchi; Yukitomo Ishi; Hiroaki Motegi; Takashi Mori; Takayuki Hashimoto; Yukayo Terashita; Shinsuke Hirabayashi; Minako Sugiyama; Akihiro Iguchi; Yuko Cho; Atsushi Manabe; Kiyohiro Houkin
    Oncology, 99, 1, 23, 31, 2021年, [国際誌]
    英語, 研究論文(学術雑誌), OBJECTIVE: Most types of intracranial germ cell tumors (IGCTs) are sensitive to chemoradiation. However, biopsy specimens are usually small and thus cannot be used for obtaining an accurate pathological diagnosis. Recently, the cerebrospinal fluid (CSF) placental alkaline phosphatase (PLAP) value has been considered a new biomarker of IGCTs. The present study aimed to evaluate the discriminatory characteristics of the CSF-PLAP value upon diagnosis and at the time of recurrence in patients with IGCTs. METHODS: Between 2015 and 2019, this study included 37 patients with tumors located in the intraventricular and/or periventricular region. The CSF-PLAP level was assessed before the patients received any treatment. The PLAP level was evaluated during and after first-line chemoradiotherapy in 7 patients with IGCTs. The CSF-PLAP values were compared according to histological diagnosis, and the correlation between these values and radiographical features was assessed. The CSF-PLAP values of 6 patients with IGCTs with suspected recurrence were evaluated based on neuroimaging findings. RESULTS: The CSF-PLAP values were significantly higher in patients with IGCTs than in those with other types of brain tumor (n = 19 vs. 18; median: 359.0 vs. <8.0 pg/mL). The specificity and sensitivity were 88 and 95%, respectively, with a cutoff value of 8.0 pg/mL. In patients with IGCT, the CSF-PLAP value was higher in patients with germinoma than in those with nongerminomatous germ cell tumors (n = 12 vs. 7; median: 415.0 vs. 359.0 pg/mL). Regarding the time course, the CSF-PLAP value decreased to below the detection limit after the reception of first-line chemoradiotherapy in all 7 patients. A significant correlation was observed between the initial CSF-PLAP value and the tumor reduction volume after receiving first-line chemoradiotherapy (p < 0.0003, R2 = 0.6165, logY = 1.202logX - 1.727). Among the patients with suspected IGCT recurrence (n = 6), the CSF-PLAP value was high in patients with recurrence (n = 3; median: 259.0 pg/mL), and that in patients (n = 3) without recurrence was below the lower detection limit. CONCLUSIONS: The CSF-PLAP level is a useful biomarker during the initial diagnosis of IGCTs and at the time of recurrence. It may be associated with the volume of germinomatous components of tumors.
  • DIAGNOSTIC CAPABILITY OF CSF-PLAP ON INTRACRANIAL GERM CELL TUMOR
    Michinari Okamoto; Shigeru Yamaguchi; Yukitomo Ishi; Hiroaki Motegi; Yukayo Terashita; Shinsuke Hirabayashi; Minako Sugiyama; Yuko Cho; Akihiro Iguchi; Atushi Manabe; Kiyohiro Houkin
    NEURO-ONCOLOGY, 22, 334, 334, 2020年12月, [査読有り]
    英語
  • Refractory malignant hepatocellular tumor consisting of hepatocellular carcinoma and hepatoblastoma in a 10-year-old male
    Minako Sugiyama; Shinsuke Hirabayashi; Yukayo Terashita; Yuko Cho; Akihiro Iguchi; Yoshihito Ohhara; Daisuke Abo; Shohei Honda; Emi Takakuwa; Atsushi Manabe
    Authorea, Inc., 2020年06月22日
  • Successful treatment of dumbbell-shaped Hodgkin lymphoma with massive sacral bone destruction.
    Minako Sugiyama; Yukayo Terashita; Yuko Cho; Akihiro Iguchi; Ryuta Arai; Emi Takakuwa; Shohei Honda; Atsushi Manabe
    Pediatric blood & cancer, 67, 5, e28210, 2020年05月, [査読有り], [国際誌]
    英語
  • 発汗過多、成長障害を契機に診断に至った神経芽腫の一例
    橋本 佳帆子; 中山 加奈子; 山口 健史; 原 和也; 寺下 友佳代; 杉山 未奈子; 長 祐子; 井口 晶裕; 本多 昌平; 中村 明枝; 真部 淳
    臨床小児医学, 67, 1-6, 84, 89, (財)小児愛育協会, 2020年03月
    日本語
  • Septic Arthritis Caused by Mycobacterium Kansasii in a Bone Marrow Transplant Recipient.
    Minako Sugiyama; Yukayo Terashita; Kazuya Hara; Yuko Cho; Tsuyoshi Asano; Akihiro Iguchi
    Journal of pediatric hematology/oncology, 2020年02月11日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), We report an 18-year-old female individual with septic arthritis due to Mycobacterium kansasii. Three years and 6 months before arthritis, the patient underwent bone marrow transplantation and developed severe chronic graft-versus-host disease. The arthritis was refractory to medication, and she underwent joint lavage of the right foot, hip joint, and elbow joint. After surgery, her joint symptoms were relieved, and chronic graft-versus-host disease remitted more easily. It is important that we maintain a high index of suspicion for mycobacterial arthritis and diagnose it early when immunosuppressed patients experience chronic pain and joint swelling.
  • Immune thrombocytopenia in a case of trisomy 18.
    Minako Sugiyama; Yukayo Terashita; Atsuhito Takeda; Akihiro Iguchi; Atsushi Manabe
    Pediatrics international : official journal of the Japan Pediatric Society, 62, 2, 240, 242, 2020年02月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Corticosteroid-induced glaucoma in pediatric patients with hematological malignancies.
    Minako Sugiyama; Yukayo Terashita; Kazuya Hara; Yuko Cho; Akihiro Iguchi; Shinki Chin; Atsushi Manabe
    Pediatric blood & cancer, 66, 12, e27977, 2019年12月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Corticosteroids, especially dexamethasone, play a critical role in chemotherapy for pediatric hematological malignancies. We previously observed that patients with complaints of headache or photophobia during corticosteroid administration had high intraocular pressure (IOP). PROCEDURE: We measured IOP during corticosteroid administration in 15 patients with acute leukemia or lymphoma undergoing treatment at our institution from January 2016 to December 2018. IOP was measured by an ophthalmologist within seven days of the initiation of standard dose of corticosteroid, which was defined as 60 mg/m2 /day for prednisolone and 10 mg/m2 /day for dexamethasone. RESULTS: Fifteen patients received 52 courses of chemotherapy containing corticosteroids. IOP exceeded 21 mmHg among 13 patients in 28 courses. Twelve of the 13 patients were administered topical treatment, and six of the 12 patients needed additional diuretic agents. IOP during the chemotherapy courses containing dexamethasone was significantly higher compared with IOP during the chemotherapy courses containing prednisolone. Only two patients complained of symptoms, such as headache and photophobia, and one of the two patients underwent trabeculotomy. Funduscopic findings were normal in all patients. There was a dose-associated decrease in IOP with reduction of dexamethasone dose. CONCLUSIONS: IOP should be measured during administration of substantial corticosteroid doses even in patients with no symptoms. Further investigations regarding the level of IOP for intervention need to be conducted.
  • Outbreak of aseptic meningitis caused by echovirus 30 in Kushiro, Japan in 2017.
    Yuji Maruo; Masanori Nakanishi; Yasuto Suzuki; Yosuke Kaneshi; Yukayo Terashita; Masashi Narugami; Michi Takahashi; Sho Kato; Ryota Suzuki; Akiko Goto; Masahiro Miyoshi; Hideki Nagano; Takahisa Sugisawa; Motohiko Okano
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 116, 34, 38, 2019年07月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Echovirus 30 (E30) is one of the most common causative agents for aseptic meningitis. OBJECTIVES: In the autumn of 2017, there was an outbreak caused by E30 in Kushiro, Hokkaido, Japan. The aim of this study was to characterize this outbreak. STUDY DESIGN: Fifty-nine patients were admitted to the Department of Pediatrics, Kushiro Red Cross Hospital (KRCH) with clinical diagnosis of aseptic meningitis. Among those, 36 patients were finally diagnosed as E30-associated aseptic meningitis by the detection of viral RNA using reverse transcription-polymerase chain reaction (RT-PCR) and/or the evidence of more than four-fold rise in neutralizing antibody (NA) titers in the convalescent phase relative to those in the acute phase. We investigated these 36 confirmed cases. RESULTS: The median age was 6 years (range: 6 months-14 years). The positive signs and symptoms were as follows: fever (100%), headache (94%), vomiting (92%), jolt accentuation (77%), neck stiffness (74%), Kernig sign (29%), and abdominal pain (28%). The median cerebrospinal fluid (CSF) white cell count, neutrophil count, and lymphocyte count were 222/μL (range: 3-1434/μL), 144/μL (range: 1-1269/μL), and 85/μL (range: 2-354/μL), respectively. Although the detected viral genes demonstrated same cluster, they were different from E30 strains observed in Japan between 2010 and 2014. CONCLUSION: We mainly showed clinical and virological features of the E30-associated aseptic meningitis outbreak that occurred in Kushiro. To prevent further spread of E30 infection, continuous surveillance of enterovirus (EV) circulation and standard precautions are considered essential.
  • Povidone-iodine lowers the incidence of catheter-associated bloodstream infection.
    Minako Sugiyama; Akihiro Iguchi; Yukayo Terashita; Junjiro Ohshima; Yuko Cho
    Pediatrics international : official journal of the Japan Pediatric Society, 61, 3, 230, 234, 2019年03月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Central venous (CV) catheters are required for chemotherapy but they may become a source of life-threatening infections of the bloodstream. The most effective way to disinfect the port of a CV catheter has not been established. METHODS: We report the data obtained between April 2008 and March 2010 using 83% ethanol (period I) and between April 2010 and March 2014 using 10% povidone-iodine (period II) to sterilize the access port. The participants received chemotherapy or autologous/allogeneic stem cell transplantation at the present institution. RESULTS: No significant difference was observed in patient characteristics between the two periods, such as disease, median age, or the period of neutropenia. The incidence of positive blood culture during periods I and II was 18.5% (31/168) and 11.4% (40/350; P = 0.041), respectively. The incidence of catheter-associated bloodstream infection on blood culture during periods I and II was 11.9% (20/168) and 6.3% (22/350; P = 0.043), respectively. Bacillus cereus infection was not detected during period II. CONCLUSION: The incidence of infection caused by CV catheters was significantly reduced using povidone-iodine; therefore, we recommend this procedure as part of the routine in chemotherapy.
  • Long-term outcome of renal function in children after stem cell transplantation measured by estimated glomerular filtration rate.
    Yukayo Ukeba-Terashita; Ryoji Kobayashi; Daiki Hori; Satoru Matsushima; Hirozumi Sano; Daisuke Suzuki; Masahide Nakajima; Masahiko Suzuki; Michihiko Ueno; Shoji Fujita; Kunihiko Kobayashi
    Pediatric blood & cancer, 66, 2, e27478, 2019年02月, [査読有り], [筆頭著者], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Stem cell transplantation (SCT) outcomes have improved over the last three decades, with many patients being rescued with this treatment. However, improved outcomes have led to issues with long-term sequelae. One of these sequelae in children is renal dysfunction, an index of which is estimated using glomerular filtration rate (eGFR). PROCEDURE: We retrospectively analyzed eGFR in 83 pediatric patients who received SCT. Data from all patients extended up to 12 months or more post SCT. The median follow-up time was 127.7 months (range 12.0-268.8 months). RESULTS: Eighteen patients (21.7%) had low eGFR (<90 ml/min/1.73 m2 ) post SCT. Cumulative incidence of low eGFR was 25.8 ± 2.0%. Nine (10.6%) patients had a low eGFR pre-SCT. However, pre- and post-SCT incidence of low eGFR were not correlated. Meanwhile, only two patients (2.4%) exhibited severe renal dysfunction, with eGFRs < 60 ml/min/1.73 m2 . Independent risk factors for low eGFR were solid tumor and use of fludarabine. Moreover, age at SCT ≥ 7 years was also a long-term post-SCT risk factor for low eGFR in all patients. CONCLUSION: Independent post-SCT long-term risk factors for low eGFR in children were solid tumor and use of fludarabine. Moreover, age at SCT ≥ 7 years was a post-SCT long-term risk factor for low eGFR across all patients.
  • DICER1遺伝子変異により診断したAnaplastic Sarcoma of the Kidneyの一症例
    長谷河 昌孝; 寺下 友佳代; 杉山 未奈子; 大久保 淳; 長 祐子; 井口 晶裕; 河北 一誠; 荒 桃子; 本多 昌平; 武冨 紹信; 高桑 恵美; 松野 吉宏
    日本小児血液・がん学会雑誌, 55, 4, 288, 288, (一社)日本小児血液・がん学会, 2018年10月
    日本語
  • Bortezomib combined with standard induction chemotherapy in Japanese children with refractory acute lymphoblastic leukemia.
    Akihiro Iguchi; Yuko Cho; Minako Sugiyama; Yukayo Terashita; Tadashi Ariga; Yosuke Hosoya; Shinsuke Hirabayashi; Atsushi Manabe; Keisuke Hara; Tetsuya Aiba; Tsugumi Shiokawa; Hiroko Tada; Norihiro Sato
    International journal of hematology, 106, 2, 291, 298, 2017年08月, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌), Bortezomib has been shown to be effective and well-tolerated in patients with refractory acute lymphoblastic leukemia (ALL) in the Therapeutic Advances in Childhood Leukemia trial. However, the safety and efficacy of bortezomib have not been evaluated in Japanese pediatric patients. Here, we report the results of a clinical trial designed to evaluate the safety of bortezomib combined with induction chemotherapy in Japanese children with refractory ALL. A total of six patients with B-precursor ALL were enrolled in this study. Four-dose bortezomib (1.3 mg/m2/dose) combined with two standard induction chemotherapies was used. Prolonged pancytopenia (grade 4) was observed in all patients. Four of the six patients developed severe infectious complications. Peripheral neuropathy (grade 2) occurred in five patients. The individual plasma bortezomib concentration-time profiles were not related to toxicity and efficacy. Five patients were evaluable for response, and four patients achieved complete response (CR) or CR without platelet recovery (80%). In conclusion, four-dose bortezomib (1.3 mg/m2/dose) combined with standard re-induction chemotherapy was associated with a high risk of infectious complications induced by prolonged neutropenia, although high efficacy has been achieved for Japanese pediatric patients with refractory ALL. Attention must be given to severe infectious complications when performing re-induction chemotherapy including bortezomib.
  • Graft-versus-host disease (GVHD) prophylaxis by using methotrexate decreases pre-engraftment syndrome and severe acute GVHD, and accelerates engraftment after cord blood transplantation.
    Akihiro Iguchi; Yukayo Terashita; Minako Sugiyama; Junjiro Ohshima; Tomonobu Z Sato; Yuko Cho; Ryoji Kobayashi; Tadashi Ariga
    Pediatric transplantation, 20, 1, 114, 9, 2016年02月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), GVHD and graft failure are serious problems in CBT. PES after CBT also occurs frequently and is associated with transplantation-related complications such as acute GVHD. We reviewed medical records for 70 consecutive child CBT recipients between December 1997 and April 2015. Forty-nine patients received prophylaxis against GVHD with CsA or Tac in combination with mPSL from day +7 (mPSL group), and 21 patients received CsA or Tac with MTX on day +1 and day +3 (MTX group). Neutrophil engraftment was detected in 59 patients (84.3%). Neutrophil engraftment rate in the MTX group was significantly higher than that in the mPSL group (21/21 (100%) and 38/49 (77.6%), respectively, p = 0.027). PES developed in 35 patients, and the incidence of PES in the mPSL group was significantly higher than that in the MTX group (p = 0.036). The incidence of severe acute GVHD (grade III or IV) in the MTX group was significantly lower than that in the mPSL group (p = 0.049). Although this study was a small-scale study, the results showed that increase in the rate of engraftment and decrease in the incidence of early immune reactions such as PES and severe acute GVHD could be achieved by early commencement of immunosuppression using MTX.
  • 脳原発横紋筋肉腫に対する集学的治療の経験
    長 祐子; 杉山 未奈子; 寺下 友佳代; 大島 淳二郎; 佐藤 智信; 井口 晶裕; 有賀 正; 小林 浩之; 寺坂 俊介; 橋本 孝之; 高桑 恵美
    日本小児血液・がん学会雑誌, 51, 4, 282, 282, (一社)日本小児血液・がん学会, 2014年10月
    日本語
  • 縦隔原発神経芽腫群腫瘍の4例
    工藤 絵理子; 杉山 未奈子; 寺下 友佳代; 大島 淳二郎; 佐藤 智信; 長 祐子; 井口 晶裕; 樋田 泰浩; 加賀 基知三
    日本小児血液・がん学会雑誌, 51, 4, 288, 288, (一社)日本小児血液・がん学会, 2014年10月
    日本語
  • 左上腕腫瘤で発症した芽球性形質細胞様樹状細胞腫瘍(BPDCN)の3歳女児例
    仁平 寛子; 杉山 美奈子; 寺下 友佳代; 大島 淳二郎; 佐藤 智信; 長 祐子; 井口 晶裕; 有賀 正; 高桑 恵美; 松野 吉宏
    日本小児血液・がん学会学術集会・日本小児がん看護学会・公益財団法人がんの子どもを守る会公開シンポジウムプログラム総会号, 55回・11回・18回, 223, 223, (NPO)日本小児血液・がん学会・(NPO)日本小児がん看護学会・(公財)がんの子供を守る会, 2013年11月
    日本語
  • Childhood-onset anti-MuSK antibody positive myasthenia gravis demonstrates a distinct clinical course.
    Yumi Takahashi; Minako Sugiyama; Yuki Ueda; Tomoshiro Itoh; Kazuyori Yagyu; Hideaki Shiraishi; Yukayo Ukeba-Terashita; Masanori Nakanishi; Tetsuro Nagashima; Tomihiro Imai; Masakatsu Motomura; Shinji Saitoh
    Brain & development, 34, 9, 784, 6, 2012年10月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Anti-muscle-specific tyrosine kinase antibody (MuSK-Ab) is the second most frequent autoantibody identified in adult patients with myasthenia gravis (MG). Adult patients with MuSK-Ab demonstrate characteristic clinical features but very little information is available for childhood-onset patients with MuSK-positive MG. We report a childhood-onset female patient with MuSK-positive MG. This patient showed basic clinical features compatible with adult-onset MuSK-positive MG, but some features, including spontaneous improvement, are distinct from those in adult patients. Serial examination of MuSK-Ab titers revealed a gross correlation with clinical severity despite significantly high titers throughout the clinical course. Therefore, childhood-onset MuSK-positive MG may demonstrate a distinct clinical characteristics in the early period of illness.
  • Prolonged anemia by superinfection of parvovirus B19 in a boy with enterohemorrhagic Escherichia coli O157-associated hemolytic uremic syndrome.
    Keisuke Orimo; Yukayo Ukeba; Naoko Koseki; Yoshinori Saita; Ichiro Kobayashi
    European journal of pediatrics, 168, 4, 501, 2, 2009年04月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), We report a 3-year-old boy with enterohemorrhagic Escherichia coli (EHEC) O157-associated hemolytic uremic syndrome (HUS). His anemia was associated with decreased reticulocyte count and persisted after the recovery from HUS. Superinfection of parvovirus B19 (PVB19) was proven by a transient febrile episode associated with IgM antibodies to the virus and the delayed appearance of IgG antibodies and typical rashes. We conclude that PVB19 infection could induce severe persistent anemia in EHEC-associated HUS. Reticulocytopenia is a clue to the diagnosis in such cases.
  • Apnea in a 2-month-old girl with retropharyngeal abscess.
    Yukayo Ukeba; Yosinori Saita; Tohru Matsuzawa; Tetsuji Wada; Naoki Kanai; Ichiro Kobayashi
    Acta paediatrica (Oslo, Norway : 1992), 98, 2, 210, 210, 2009年02月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
■ その他活動・業績
■ 主な担当授業
  • 基本医学研究, 2024年, 修士課程, 医学院
  • 基本医学総論, 2024年, 修士課程, 医学院
  • 医学総論, 2024年, 博士後期課程, 医学院
  • 基盤医学研究, 2024年, 博士後期課程, 医学院
  • 臨床医学研究, 2024年, 博士後期課程, 医学院
■ 共同研究・競争的資金等の研究課題
  • がん特異的糖鎖抗原を用いた切除不能小児がんに対する光免疫療法の確立:前臨床モデル
    科学研究費助成事業
    2026年04月01日 - 2029年03月31日
    長 祐子; 真部 淳; 小川 美香子; 寺下 友佳代; 植木 将弘; 河原 仁守; 後藤 悠人
    日本学術振興会, 基盤研究(C), 北海道大学, 26K10771
  • 北海道の小児がん患者における遺伝性素因の研究
    科学研究費助成事業
    2023年04月01日 - 2026年03月31日
    寺下 友佳代; 真部 淳
    小児がんの治療成績の改善により7割以上の患者に長期生存が期待できるようになったが、原疾患や治療に伴う晩期合併症や二次がんが問題となってきた。本研究では、北海道の小児がんの長期生存者の大規模コホートを用いて、生殖細胞系列遺伝子バリアント解析の意義を検討することを第1の目的とする。既に病的意義が明らかなバリアントについては結果を患者に原則開示するが、その際の遺伝カウンセリングの手順を確立することを第2の目的とする。
    研究対象者は北海道内の病院でフォローされている小児がん患者で目標症例数は100例と設定している。設定根拠は北海道内でフォローされている小児がん患者は約1000例であり、その約1割の100例が遺伝子解析に対する同意が取得できるものと想定される。初年度は20-30例の症例集積を目標としていたが、実際に約20例の症例を集積することができた。遺伝子解析は業者に委託し、1患者あたり約5-6万円、対象遺伝子は①がん易罹患性遺伝子(Cancer predisposition genes) 常染色体顕性:ALK, APC, BRCA1, BRCA2, TP53など ②がん易罹患性遺伝子(Cancer predisposition genes) 常染色体潜性:ATM, BLM, FANCA, FANCCなど ③kinase関連遺伝子: EGFR, KITなど ④がん抑制遺伝子: AXIN1, BARD1など ⑤その他の遺伝子に分類し、計158の既知の遺伝子とした。初年度助成金は予定通り全て遺伝子解析費用として使用した。今後は今回の解析結果を臨床情報との関連性について更に解析をすすめると同時に意義のある生殖細胞系列の遺伝子バリアントを認めた症例に対して遺伝カウンセリングも進め、課題を抽出していく。また次段階の症例集積に向けて患者のリクルートをすすめていく予定である。
    日本学術振興会, 基盤研究(C), 北海道大学, 23K06687